References
- Deng H, Yang H, Le W, et al. Examination of the MASH1 gene in patients with Parkinson’s disease. Biochem Biophys Res Commun. 2010;392(4):548–550.
- Samii A, Nutt JG, Ransom BR. Parkinson’s disease. The Lancet. 2004;363(9423):1783–1793.
- Guo Y, Deng X, Zheng W, et al. HLA rs3129882 variant in Chinese Han patients with late-onset sporadic Parkinson disease. Neurosci Lett. 2011;501(3):185–187.
- Guo J-F, Li K, Yu R-L, et al. Polygenic determinants of Parkinson’s disease in a Chinese population. Neurobiol Aging. 2015;36(4):1765.e1–1765.e6.
- International Parkinson Disease Genomics Consortium, Nalls MA, Plagnol V, Hernandez DG. Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: a meta-analysis of genome-wide association studies. The Lancet. 2011;377(9766):641–649.
- Hill-Burns EM, Factor SA, Zabetian CP, et al. Evidence for more than one Parkinson’s disease-associated variant within the HLA region. PloS One. 2011;6(11):e27109.
- Zhu RL, Lu XC, Tang LJ, et al. Association between HLA rs3129882 polymorphism and Parkinson’s disease: a meta-analysis. Eur Rev Med Pharmacol Sci. 2015;19(3):423–432.
- Tansey MG, Goldberg MS. Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis. 2010;37(3):510–518.
- Fiszer U, Mix E, Fredrikson S, et al. Parkinson’s disease and immunological abnormalities: increase of HLA‐DR expression on monocytes in cerebrospinal fluid and of CD45RO + T cells in peripheral blood. Acta Neurol Scand. 2009;90(3):160–166.
- Chiba S, Matsumoto H, Saitoh M, et al. A correlation study between serum adenosine deaminase activities and peripheral lymphocyte subsets in Parkinson’s disease. J Neurol Sci. 1995;132(2):170–173.
- Croisier E, Moran LB, Dexter DT, et al. Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflamm. 2005;2(1):14.
- Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson’s disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol. 2007;208(1):1–25.
- McGeer PL, Itagaki S, Boyes BE, et al. Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology. 1988;38(8):1285–1285.
- Ouchi Y, Yagi S, Yokokura M, et al. Neuroinflammation in the living brain of Parkinson’s disease. Parkinson Relat Disord. 2009;15:S200–S4.
- Hamza TH, Zabetian CP, Tenesa A, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease. Nat Genet. 2010;42(9):781–785.
- Zhao Y, Gopalai AA, Ahmad‐Annuar A, et al. Association of HLA locus variant in Parkinson’s disease. Clin Genet. 2013;84(5):501–504.
- Chiang H-L, Lee-Chen G-J, Chen CM, et al. Genetic analysis of HLA-DRA region variation in Taiwanese Parkinson’s disease. Parkinson Relat Disord. 2012;18(4):391–393.
- Ma Z-G, Liu T-W, Bo Y-L. HLA-DRA rs3129882 A/G polymorphism was not a risk factor for Parkinson’s disease in Chinese-based populations: a meta-analysis. Int J Neurosci. 2015;125(4):241–246.
- Simón-Sánchez J, Van Hilten JJ, van de Warrenburg B, et al. Genome-wide association study confirms extant PD risk loci among the Dutch. Eur J Hum Genet. 2011;19(6):655–661.
- Sharma M, On behalf of the GEO-PD Consortium, Ioannidis JPA, Aasly JO, et al. Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology. 2012;79(7):659–667.
- Glass AS, Huynh DP, Franck T, et al. Screening for mutations in synaptotagmin XI in Parkinson’s disease. J Neural Transm Suppl. 2004;68:21–28.
- Huynh DP, Scoles DR, Nguyen D, Pulst SM. The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. Hum Mol Genet. 2003;12(20):2587–2597.
- Bento CF, Ashkenazi A, Jimenez-Sanchez M, et al. The Parkinson’s disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway. Nat Commun. 2016;7(1):11803.
- Blauwendraat C, Bras JM, Nalls MA, et al. Coding variation in GBA explains the majority of the SYT11-GBA Parkinson’s disease GWAS locus. Mov Disord. 2018;33(11):1821–1823.
- Sesar A, Cacheiro P, Lopez-Lopez M, et al. Synaptotagmin XI in Parkinson’s disease: new evidence from an association study in Spain and Mexico. J Neurol Sci. 2016;362:321–325.
- Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368–376.
- Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1998;50(2):318–318.
- Reynolds AD, Stone DK, Hutter JAL, et al. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J Immunol. 2010;184(5):2261–2271.
- Montgomery SB, Sammeth M, Gutierrez-Arcelus M, et al. Transcriptome genetics using second generation sequencing in a Caucasian population. Nature. 2010;464(7289):773–777.
- Zhou LL, Zhang X, Bao QQ, et al. Association analysis of PARK16-18 variants and Parkinson’s disease in a Chinese population. J Clin Neurosci. 2014;21(6):1029–1032.
- Lin CH, Chen ML, Tai YC, Yu CY, et al. Reaffirmation of GAK, but not HLA-DRA, as a Parkinson’s disease susceptibility gene in a Taiwanese population. Am J Med Genet. 2013;162(8):841–846.
- Ming-ShuYou-Sheng M, Zhuo-Hua XW, et al. Association analysis of HLA-DRA in Chinese patients with sporadic Parkinson’s disease. Int J Physiol Pathophysiol Pharmacol. 2015; 7(4):185–194.
- Rui Q, Ze-Hen XU, Xin-Lingh Y, et al. Correlation between ATP13A2 gene polymorphism and Parkinson’s disease in patients in Xinjiang. J Shanxi Med Univ. 2019; 50(2):220–226.